MREO

Mereo BioPharma Group plc

Price Chart

Latest Quote

$0.31

-0.01 (-4.41%)

Current Price

Previous Close	$0.32
Open	$0.31
Day High	$0.33
Day Low	$0.31
Volume	627,983

Fetched: 2026-06-24T16:29:00

Stock Information

Shares Outstanding	159.62M
Cash Equivalents	$36.22M
Revenue	$500K
Net Income	$-35.71M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$49.18M
EPS (TTM)	$-0.20
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$15.22M
Sales	$500K
Income	$-35.71M
Book/sh	$0.21
Cash/sh	$0.23
Employees	39

Financial Ratios

Quick Ratio	6.17
Current Ratio	6.48

Returns & Margins

ROA	-41.21%
ROE	-75.87%
Gross Margin	73.40%
Operating Margin	-7182.20%

Ownership

Insider Ownership	0.96%
Institutional Ownership	47.90%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-8.21
P/S	98.36
P/B	1.45

Analyst Data

Recommendation	none
Target Price	$1.70

Technical Indicators

SMA20	$0.32
SMA50	$0.30
SMA200	$0.98
RSI	38.22
ATR	0.0271

Shares Float	117.16M
Short Float	6.29%
Short Ratio	1.44
Volatility	0.28
Rel Volume	0.11

Performance History

Week	+5.51%
Month	+10.83%
Quarter	-8.30%
6 Months	-84.60%
YTD	-39.59%
Year	-88.76%
3 Years	-77.99%
5 Years	-90.55%
10 Years	-95.26%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-24	$0.31	627,983
2026-06-23	$0.32	1,566,600
2026-06-22	$0.32	1,386,900
2026-06-18	$0.31	1,440,200
2026-06-17	$0.31	3,262,200
2026-06-16	$0.29	1,227,800
2026-06-15	$0.30	1,538,800
2026-06-12	$0.31	2,124,700
2026-06-11	$0.31	2,961,100
2026-06-10	$0.31	2,396,700
2026-06-09	$0.31	1,435,400
2026-06-08	$0.31	2,453,900
2026-06-05	$0.31	3,541,600
2026-06-04	$0.32	3,160,200
2026-06-03	$0.33	7,151,700
2026-06-02	$0.34	8,029,300
2026-06-01	$0.31	3,640,500
2026-05-29	$0.34	3,892,500
2026-05-28	$0.34	5,783,500
2026-05-27	$0.33	57,856,500
2026-05-26	$0.33	22,878,500

About Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

📰 Latest News

European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading

MT Newswires • 2026-06-24T15:15:07Z

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires • 2026-06-17T15:10:44Z

European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading

MT Newswires • 2026-06-15T15:09:48Z

European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week

MT Newswires • 2026-06-12T15:14:33Z

European Equities Traded in US as ADRs Rise in Thursday Trading

MT Newswires • 2026-06-11T15:09:49Z

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires • 2026-06-08T15:10:25Z

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading

MT Newswires • 2026-06-03T15:10:58Z

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

MT Newswires • 2026-06-02T15:08:08Z

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

MT Newswires • 2026-06-01T15:11:54Z

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week

MT Newswires • 2026-05-29T15:11:57Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$133,000	$0	$2,574,000	$-1,146,000
Cost Of Revenue	$133,000	$0	$2,574,000	$-1,146,000
Total Revenue	$500,000	$0	$10,000,000	$0
Operating Revenue	$500,000	$0	$10,000,000	$0
Expenses
Interest Expense	$255,000	$1,370,000	$2,881,000	$4,175,000
Total Expenses	$38,757,000	$45,715,000	$37,136,000	$52,698,000
Other Income Expense	$-5,539,000	$791,000	$-2,112,000	$13,095,000
Net Non Operating Interest Income Expense	$1,918,000	$1,671,000	$-750,000	$-3,335,000
Interest Expense Non Operating	$255,000	$1,370,000	$2,881,000	$4,175,000
Operating Expense	$38,624,000	$45,715,000	$34,562,000	$53,844,000
Other Operating Expenses	$-2,150,000	$-1,649,000	$-1,280,000	$-1,728,000
General And Administrative Expense	$23,008,000	$26,434,000	$18,424,000	$26,107,000
Other Non Operating Income Expenses	-	-	$-10,000	$1,086,000
Total Other Finance Cost	-	-	-	$49,618
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-41,878,000	$-43,253,000	$-29,466,000	$-42,220,000
Net Interest Income	$1,918,000	$1,671,000	$-750,000	$-3,335,000
Interest Income	$2,173,000	$3,041,000	$2,131,000	$840,000
Normalized Income	$-36,339,000	$-44,044,000	$-27,401,836	$-54,028,188
Net Income From Continuing And Discontinued Operation	$-41,878,000	$-43,253,000	$-29,466,000	$-42,220,000
Total Operating Income As Reported	$-40,107,000	$-47,364,000	$-28,416,000	$-54,426,000
Net Income Common Stockholders	$-41,878,000	$-43,253,000	$-29,466,000	$-42,220,000
Net Income	$-41,878,000	$-43,253,000	$-29,466,000	$-42,220,000
Net Income Including Noncontrolling Interests	$-41,878,000	$-43,253,000	$-29,466,000	$-42,220,000
Net Income Continuous Operations	$-41,878,000	$-43,253,000	$-29,466,000	$-42,220,000
Pretax Income	$-41,878,000	$-43,253,000	$-29,998,000	$-42,938,000
Interest Income Non Operating	$2,173,000	$3,041,000	$2,131,000	$840,000
Operating Income	$-38,257,000	$-45,715,000	$-27,136,000	$-52,698,000
Gross Profit	$367,000	$0	$7,426,000	$1,146,000
Average Dilution Earnings	-	-	-	$0
Special Income Charges	-	-	-	$0
Per Share
Diluted EPS	$-0.25	$-0.30	$-0.20	$-0.36
Basic EPS	$-0.25	$-0.30	$-0.20	$-0.36
Other
Tax Effect Of Unusual Items	$0	$0	$-37,836	$200,812
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-34,935,000	$-41,586,000	$-23,954,000	$-49,883,000
Total Unusual Items	$-5,539,000	$791,000	$-2,102,000	$12,009,000
Total Unusual Items Excluding Goodwill	$-5,539,000	$791,000	$-2,102,000	$12,009,000
Reconciled Depreciation	$1,149,000	$1,088,000	$1,061,000	$889,000
EBITDA (Bullshit earnings)	$-40,474,000	$-40,795,000	$-26,056,000	$-37,874,000
EBIT	$-41,623,000	$-41,883,000	$-27,117,000	$-38,763,000
Diluted Average Shares	$159,423,926	$147,924,853	$131,890,784	$113,986,667
Basic Average Shares	$159,423,926	$147,924,853	$131,890,784	$113,986,667
Diluted NI Availto Com Stockholders	$-41,878,000	$-43,253,000	$-29,466,000	$-42,220,000
Tax Provision	$0	$0	$-532,000	$-718,000
Gain On Sale Of Security	$-5,539,000	$791,000	$-2,102,000	$12,009,000
Research And Development	$17,766,000	$20,930,000	$17,418,000	$29,465,000
Selling General And Administration	$23,008,000	$26,434,000	$18,424,000	$26,107,000
Other Gand A	$23,008,000	$26,434,000	$18,424,000	$26,107,000
Gain On Sale Of Ppe	-	-	-	$0
Restructuring And Mergern Acquisition	-	-	-	-

Fetched: 2026-06-22

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$40,400,000	$60,326,000	$49,448,000	$51,402,000
Total Assets	$45,917,000	$76,390,000	$66,499,000	$77,413,000
Total Non Current Assets	$897,000	$1,627,000	$2,739,000	$2,216,000
Goodwill And Other Intangible Assets	$516,000	$643,000	$1,089,000	$0
Current Assets	$45,020,000	$74,763,000	$63,760,000	$75,197,000
Other Current Assets	$141,000	$60,000	$340,000	$1,434,000
Prepaid Assets	$1,904,000	$1,651,000	$2,267,000	$2,833,000
Receivables	$1,983,000	$3,250,000	$3,732,000	$2,748,000
Other Receivables	$1,497,000	$2,786,000	$3,133,000	$1,569,000
Taxes Receivable	$486,000	$464,000	$599,000	$1,179,000
Cash Cash Equivalents And Short Term Investments	$40,992,000	$69,802,000	$57,421,000	$68,182,000
Cash And Cash Equivalents	$40,992,000	$69,802,000	$57,421,000	$68,182,000
Other Intangible Assets	-	-	$1,089,000	$24,116,000
Cash Equivalents	-	-	-	$51,104,000
Cash Financial	-	-	-	$5,230,000
Debt
Total Debt	$202,000	$6,429,000	$5,952,000	$15,369,000
Long Term Debt And Capital Lease Obligation	$0	$187,000	$5,300,000	$1,479,000
Current Debt And Capital Lease Obligation	$202,000	$6,242,000	$652,000	$13,890,000
Current Debt	-	$5,535,000	-	$13,326,000
Other Current Borrowings	-	$5,535,000	-	$13,326,000
Long Term Debt	-	-	$4,394,000	-
Liabilities
Total Liabilities Net Minority Interest	$5,001,000	$15,421,000	$15,962,000	$26,011,000
Total Non Current Liabilities Net Minority Interest	$699,000	$1,573,000	$6,476,000	$1,636,000
Other Non Current Liabilities	$661,000	$565,000	$764,000	$182,000
Derivative Product Liabilities	$38,000	$821,000	$412,000	$157,000
Current Liabilities	$4,302,000	$13,848,000	$9,486,000	$24,375,000
Other Current Liabilities	$30,000	$61,000	$30,000	$1,355,000
Current Deferred Liabilities	$296,000	$296,000	$711,000	$0
Payables And Accrued Expenses	$3,546,000	$5,248,000	$6,469,000	$7,267,000
Payables	$1,781,000	$3,445,000	$3,008,000	$3,694,000
Other Payable	$95,000	$235,000	-	$25,000
Total Tax Payable	$353,000	$770,000	$662,000	$202,000
Accounts Payable	$1,333,000	$2,440,000	$2,346,000	$3,492,000
Equity
Common Stock Equity	$40,916,000	$60,969,000	$50,537,000	$51,402,000
Total Equity Gross Minority Interest	$40,916,000	$60,969,000	$50,537,000	$51,402,000
Stockholders Equity	$40,916,000	$60,969,000	$50,537,000	$51,402,000
Gains Losses Not Affecting Retained Earnings	$-10,823,000	$-18,849,000	$-17,485,000	$-21,687,000
Other Equity Adjustments	$-10,823,000	$-18,849,000	$-17,485,000	$-21,687,000
Retained Earnings	$-501,018,000	$-462,883,000	$-419,630,000	$-404,575,000
Other
Ordinary Shares Number	$795,658,504	$775,728,034	$700,293,689	$623,925,489
Share Issued	$795,658,504	$775,728,034	$701,217,089	$624,928,519
Tangible Book Value	$40,400,000	$60,326,000	$49,448,000	$51,402,000
Invested Capital	$40,916,000	$66,504,000	$54,931,000	$64,728,000
Working Capital	$40,718,000	$60,915,000	$54,274,000	$50,822,000
Capital Lease Obligations	$202,000	$894,000	$1,558,000	$2,043,000
Total Capitalization	$40,916,000	$60,969,000	$54,931,000	$51,402,000
Additional Paid In Capital	$549,622,000	$539,642,000	$486,107,000	$476,521,000
Capital Stock	$3,135,000	$3,059,000	$2,775,000	$2,478,000
Common Stock	$3,135,000	$3,059,000	$2,775,000	$2,478,000
Long Term Capital Lease Obligation	$0	$187,000	$906,000	$1,479,000
Current Capital Lease Obligation	$202,000	$707,000	$652,000	$564,000
Pensionand Other Post Retirement Benefit Plans Current	$228,000	$2,001,000	$1,624,000	$1,863,000
Current Accrued Expenses	$1,765,000	$1,803,000	$3,461,000	$3,573,000
Net PPE	$381,000	$984,000	$1,650,000	$2,216,000
Accumulated Depreciation	$-1,085,000	$-949,000	$-800,000	$-736,000
Gross PPE	$1,466,000	$1,933,000	$2,450,000	$2,952,000
Leases	$764,000	$712,000	$710,000	$675,000
Other Properties	$248,000	$298,000	$296,000	$422,000
Machinery Furniture Equipment	$210,000	$196,000	$199,000	$190,000
Buildings And Improvements	$244,000	$727,000	$1,245,000	$1,665,000
Properties	$0	$0	$0	$0
Treasury Stock	-	$0	$1,230,000	$1,335,000
Treasury Shares Number	-	-	$923,400	$1,003,030
Foreign Currency Translation Adjustments	-	-	-	$-2,169,000
Current Provisions	-	-	-	$4,822,000
Long Term Provisions	-	-	-	-

Fetched: 2026-06-22

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-31,291,000	$-33,533,000	$-21,551,000	$-48,834,000
Operating Activities
Operating Cash Flow	$-30,971,000	$-32,834,000	$-21,132,000	$-48,821,000
Cash Flow From Continuing Operating Activities	$-30,971,000	$-32,834,000	$-21,132,000	$-48,821,000
Operating Gains Losses	$5,435,000	$-791,000	$2,102,000	$-12,009,000
Investing Activities
Capital Expenditure	$-320,000	$-699,000	$-419,000	$-13,000
Investing Cash Flow	$-20,000	$-699,000	$-419,000	$1,987,000
Cash Flow From Continuing Investing Activities	$-20,000	$-699,000	$-419,000	$1,987,000
Net Other Investing Changes	$300,000	-	-	$-814,464
Financing Activities
Issuance Of Capital Stock	$39,000	$47,000,000	$11,605,000	$0
Financing Cash Flow	$327,000	$46,147,000	$7,973,000	$200,000
Cash Flow From Continuing Financing Activities	$327,000	$46,147,000	$7,973,000	$200,000
Net Other Financing Charges	$-199,000	$-853,000	$-444,000	$200,000
Net Common Stock Issuance	$39,000	$47,000,000	$11,605,000	$0
Common Stock Issuance	$39,000	$47,000,000	$11,605,000	$0
Cash Dividends Paid	-	-	-	$0
Repurchase Of Capital Stock	-	-	-	-
Other
Interest Paid Supplemental Data	$29,000	$21,000	$884,000	-
End Cash Position	$40,992,000	$69,802,000	$57,421,000	$68,182,000
Beginning Cash Position	$69,802,000	$57,421,000	$68,182,000	$127,398,000
Effect Of Exchange Rate Changes	$1,854,000	$-233,000	$2,818,000	$-12,582,000
Changes In Cash	$-30,664,000	$12,614,000	$-13,579,000	$-46,634,000
Proceeds From Stock Option Exercised	$487,000	$0	-	$0
Net Intangibles Purchase And Sale	$-300,000	$-699,000	$-419,000	$0
Purchase Of Intangibles	$-300,000	$-699,000	$-419,000	$0
Net PPE Purchase And Sale	$-20,000	$0	$0	$1,987,000
Purchase Of PPE	$-20,000	$0	$0	$-13,000
Change In Working Capital	$-3,203,000	$-369,000	$-1,593,000	$-2,352,000
Change In Other Current Liabilities	$-743,000	$-654,000	$-578,000	$-878,000
Change In Payables And Accrued Expense	$-3,772,000	$-1,046,000	$-1,973,000	$1,461,000
Change In Accrued Expense	$-2,394,000	$-1,192,000	$-710,000	$844,000
Change In Payable	$-1,378,000	$146,000	$-1,263,000	$617,000
Change In Account Payable	$-1,378,000	$146,000	$-1,263,000	$617,000
Change In Prepaid Assets	$-84,000	$2,980,000	$502,000	$532,000
Change In Receivables	$1,396,000	$-1,649,000	$456,000	$-3,467,000
Other Non Cash Items	$-72,000	$3,101,000	$1,840,000	$2,103,000
Stock Based Compensation	$7,598,000	$7,390,000	$4,924,000	$4,768,000
Depreciation Amortization Depletion	$1,149,000	$1,088,000	$1,061,000	$889,000
Depreciation And Amortization	$1,149,000	$1,088,000	$1,061,000	$889,000
Amortization Cash Flow	$465,000	$438,000	$395,000	$0
Amortization Of Intangibles	$465,000	$438,000	$395,000	$0
Depreciation	$684,000	$650,000	$666,000	$889,000
Gain Loss On Investment Securities	$-909,000	$419,000	$-245,000	$-9,286,000
Net Foreign Currency Exchange Gain Loss	$6,344,000	$-1,210,000	$2,347,000	$-2,723,000
Net Income From Continuing Operations	$-41,878,000	$-43,253,000	$-29,466,000	$-42,220,000
Repayment Of Debt	-	$0	$-3,188,000	$-1,133,957
Income Tax Paid Supplemental Data	-	$0	-	-
Net Issuance Payments Of Debt	-	$0	$-3,188,000	$-1,133,957
Net Long Term Debt Issuance	-	$0	$-3,188,000	$-1,133,957
Long Term Debt Payments	-	$0	$-3,188,000	$-1,133,957
Sale Of PPE	-	-	$0	$2,000,000
Issuance Of Debt	-	-	-	$0
Interest Paid Cff	-	-	-	$0
Long Term Debt Issuance	-	-	-	$0
Interest Received Cfi	-	-	-	$842,299
Net Business Purchase And Sale	-	-	-	$0
Purchase Of Business	-	-	-	$0
Sale Of Intangibles	-	-	-	$1,795,936
Taxes Refund Paid	-	-	-	$-1,850,395
Provisionand Write Offof Assets	-	-	-	$255,352
Gain Loss On Sale Of PPE	-	-	-	$0
Common Stock Payments	-	-	-	-
Net Investment Purchase And Sale	-	-	-	-
Sale Of Investment	-	-	-	-
Sale Of Business	-	-	-	-
Asset Impairment Charge	-	-	-	-

Fetched: 2026-06-22